As a very low percentage of renal cell carcinoma (RCC) cases have been found to exhibit p53 mutations55 (IARC p53 Database: http://p53.iarc.fr/), we chose RCC as the basis for study of whether ABRO1 expression correlates with p53 expression. This evidence concerns the gene ABRAXAS2 and renal cell adenocarcinoma.